Virginia Kaklamani, MD
Medical Oncology · San Antonio, TXNPI 1841235439
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $496,990 of the $787,450 with a category attached, or 63.1%. 26 manufacturers reported payments, led by Gilead at 27.4% of the total. Among medical oncology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 556 payments — averaging $1416.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$216K
- Pfizer$91K
- AstraZeneca$78K
- Novartis$75K
- Stemline Therapeutics Inc.$55K
- Genentech USA, Inc.$53K
- plus $220K from 20 others
Across 606 payments — averaging $7740.81 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Daiichi Sankyo Inc.$964K
- Novartis$929K
- Genentech, Inc.$913K
- Eli Lilly$719K
- Radius Health, Inc.$285K
- Eisai Inc.$252K
- plus $629K from 10 others
What the payments were for
- Consulting fees$245,14731%
- Speaking & faculty fees$496,99063%
- Grants$2500%
- Travel & lodging$35,7295%
- Food & beverage$7,5021%
- Education$850%
- Other$1,7470%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 118 | $216,032 |
| Pfizer(2 entities) | 42 | $91,194 |
| AstraZeneca | 90 | $77,541 |
| Novartis | 69 | $74,983 |
| Stemline Therapeutics Inc. | 27 | $54,675 |
| Genentech USA, Inc. | 29 | $52,614 |
| Puma Biotechnology, Inc. | 40 | $40,241 |
| Daiichi Sankyo Inc. | 30 | $37,118 |
| Lilly USA, LLC | 13 | $35,382 |
| Bristol Myers Squibb | 21 | $34,318 |
| Seagen Inc. | 24 | $23,450 |
| Eli Lilly | 6 | $12,800 |
| Immunomedics, Inc. | 8 | $10,000 |
| Eisai Inc. | 7 | $5,704 |
| Tersera Therapeutics LLC | 7 | $5,524 |
| Sirtex Medical Inc | 3 | $3,348 |
| Merck | 6 | $2,539 |
| Sanofi | 1 | $2,517 |
| Radius Health, Inc. | 1 | $2,250 |
| Athenex Pharmaceutical Division, LLC | 4 | $2,000 |
| F. Hoffmann-la Roche AG | 2 | $1,855 |
| Bayer | 1 | $1,199 |
| Amgen | 3 | $61 |
| AVEO Pharmaceuticals, Inc. | 1 | $43 |
| Tempus AI, Inc | 2 | $42 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Trodelvy$222,305
- Enhertu$65,045
- TALZENNA$52,009
- KISQALI$51,421
- Orserdu$45,514
- Nerlynx$39,782
- PIQRAY$36,780
- Phesgo$35,099
- Abraxane$32,733
- IBRANCE$31,130
- VERZENIO$26,389
- Kadcyla$23,663
- TUKYSA$23,450
- LYNPARZA$8,355
- Halaven$5,625
- ZOLADEX$5,487
- Perjeta$4,950
- SIR-Spheres Microspheres$3,348
- TECENTRIQ$3,015
- Oral Paclitaxel$2,000
How this compares
$787,450 in reported general payments places this provider in the 95th percentile of 495 medical oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KisqaliRibociclib Succinate | 63 | $1,086,298 |
| IbrancePalbociclib | 62 | $957,260 |
| OrserduElacestrant Hcl | 15 | $349,352 |
| TruqapCapivasertib | 15 | $344,274 |
| TalzennaTalazoparib Tosylate | 11 | $202,400 |
| Exemestane | 56 | $10,395 |
| Anastrozole | 463 | $8,119 |
| VeozahFezolinetant | 11 | $5,888 |
| Letrozole | 82 | $1,772 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 48 | $1,366 |
| Prochlorperazine Maleate | 55 | $977 |
| Alendronate Sodium | 105 | $928 |
| Morphine Sulfate ErMorphine Sulfate | 24 | $755 |
| Tamoxifen Citrate | 29 | $633 |
| Ondansetron Hcl | 20 | $468 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance, Talzenna | $91,194 | $1,159,66073 claims |
| NovartisKisqali | $74,983 | $1,086,29863 claims |
| Stemline Therapeutics Inc.Orserdu | $54,675 | $349,35215 claims |
| AstraZenecaTruqap | $77,541 | $344,27415 claims |
| Lilly USA, LLCOlanzapine | $35,382 | $7617 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 495 medical oncology providers in Texas.
Other medical oncology in San Antonio
- Vijay GunugantiSan Antonio$1.5M
- John SarantopoulosSan Antonio$588K
- Sukeshi AroraSan Antonio$188K
- Anthony TolcherSan Antonio$125K
- Zohra NooruddinSan Antonio$113K
- Moshe LevyDallas$5.1M
- Suresh RatnamMcAllen$3M
- Roy HerbstHouston$1.9M
- Andrew WhiteleyDallas$1.7M
- Eric NadlerDallas$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.